Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

p53 Mutations in Human Cancers

Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms

Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765

Discovery and saturation analysis of cancer genes across 21 tumour types

Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096

Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations

Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559

T antigen is bound to a host protein in SY40-transformed cells

Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456

p53 in health and disease

Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,351

Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206

TP53 mutations in human cancers: origins, consequences, and clinical use.

Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199

Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas

Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,097

Tumor spectrum analysis in p53-mutant mice

Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051

The p53 proto-oncogene can act as a suppressor of transformation

Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967

Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells

Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,814

p53 mutations in cancer

Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647

Unravelling mechanisms of p53-mediated tumour suppression

Bieging-Rolett, K. T., Mello, S. S., & Attardi, L. D. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3711 · Cited by 1,454

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308

Mutant p53: one name, many proteinsPreprint

Freed-Pastor, W. A., & Prives, C. L. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,290

Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome

Srivastava, S. K., Zou, Z., Pirollo, K. F., Blattner, W. A., & Chang, E. H. (1990) · Nature · doi:10.1038/348747a0 · Cited by 1,210

P53 in survival, death and metabolic health: a lifeguard with a licence to kill.

Kruiswijk, F., Labuschagne, C. F., & Vousden, K. H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4007 · Cited by 1,080

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome

Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067

p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.

Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S. D., Willson, J. K. V., Hamilton, S. R., & Vogelstein, B. (1990) · PubMed · Cited by 1,065

Role of Tyrosine Kinase Inhibitors in Cancer Therapy

Arora, A., & Scholar, E. M. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084145 · Cited by 1,037

Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis

Rivlin, N., Brosh, R., Oren, M., & Rotter, V. (2011) · Genes & Cancer · doi:10.1177/1947601911408889 · Cited by 1,033

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

Heise, C. C., Sampson-Johannes, A., Williams, A., McCormick, F. P., Hoff, D. D. V., & Kirn, D. H. (1997) · Nature Medicine · doi:10.1038/nm0697-639 · Cited by 941

Oncogenic Forms of p53 Inhibit p53-Regulated Gene Expression

Kern, S. E., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K. W., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940

Gain of function mutations in p53

Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894

TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes

Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway

Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R. N., Stewart, C. J. R., Fereday, S., Caldas, C., DeFazio, A., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2696 · Cited by 815

Pharmacological Rescue of Mutant p53 Conformation and Function

Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 802

Mutant p53 drives invasion by promoting integrin recycling

Muller, P. A. J., Caswell, P. T., Doyle, B., Iwanicki, M. P., Tan, E. H., Karim, S., Lukashchuk, N., Gillespie, D. A., Ludwig, R. L., Gosselin, P., et al. (2009) · Cell · doi:10.1016/j.cell.2009.11.026 · Cited by 796

Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53

Michalovitz, D., Halevy, O., & Oren, M. (1990) · Cell · doi:10.1016/0092-8674(90)90113-s · Cited by 769

Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors

Issaeva, N., Bozko, P. M., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M. G., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 760

Drugging the p53 pathway: understanding the route to clinical efficacy

Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 742

Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation

Parada, L. F., Land, H., Weinberg, R. A., Wolf, D., & Rotter, V. (1984) · Nature · doi:10.1038/312649a0 · Cited by 734

TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data: Human Mutation

Bouaoun, L., Sonkin, D., Ardin, M., Hollstein, M., Byrnes, G., Zavadil, J., & Olivier, M. (2016) · Human Mutation · doi:10.1002/humu.23035 · Cited by 730

Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse.

DeLeo, A. B., Jay, G. D., Appella, E., DuBois, G. C., Law, L. W., & Old, L. J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.5.2420 · Cited by 721

Participation of p53 cellular tumour antigen in transformation of normal embryonic cells

Eliyahu, D., Raz, A., Gruß, P., Givol, D., & Oren, M. (1984) · Nature · doi:10.1038/312646a0 · Cited by 720

Wild-type p53 can inhibit oncogene-mediated focus formation.

Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi-Kimhi, O., & Oren, M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.22.8763 · Cited by 687

The mitochondrial p53 pathway

Vaseva, A. V., & Moll, U. M. (2008) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2008.10.005 · Cited by 634

Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation

Milner, J., & Medcalf, E. (1991) · Cell · doi:10.1016/0092-8674(91)90384-b · Cited by 612

Tumor Suppressive Functions of p53Preprint

Zilfou, J. T., & Lowe, S. W. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001883 · Cited by 611

tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors

Berghmans, S., Murphey, R. D., Wienholds, E., Neuberg, D. S., Kutok, J. L., Fletcher, C. D. �., Morris, J. P., Liu, T. X., Schulte‐Merker, S., Kanki, J. P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406252102 · Cited by 607

The expanding universe of p53 targets

Menendez, D., Inga, A., & Resnick, M. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2730 · Cited by 568

The Differential Effects of Mutant p53 Alleles on Advanced Murine Lung Cancer

Jackson, E. L., Olive, K. P., Tuveson, D. A., Bronson, R., Crowley, D., Brown, M., & Jacks, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2193 · Cited by 553

Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53

Jenkins, J. R., Rudge, K., & Currie, G. A. (1984) · Nature · doi:10.1038/312651a0 · Cited by 543

An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma

Ribeiro, R. C., Sandrini, F., Figueiredo, B., Zambetti, G. P., Michalkiewicz, E., Lafferty, A. R., DeLacerda, L., Rabin, M., Cadwell, C., Sampaio, G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161479898 · Cited by 541

Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome

Kratz, C. P., Achatz, M. I., Brugières, L., Frebourg, T., Garber, J. E., Greer, M.-L. C., Hansford, J. R., Janeway, K. A., Kohlmann, W. K., McGee, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0408 · Cited by 534

Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression

Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Broz, D. K., Basak, S., Park, E. J., McLaughlin, M. E., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.035 · Cited by 533

Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth

Zhu, J., Sammons, M. A., Donahue, G., Dou, Z., Vedadi, M., Getlik, M., Barsyte-Lovejoy, D., Al-awar, R., Katona, B. W., Shilatifard, A., et al. (2015) · Nature · doi:10.1038/nature15251 · Cited by 493

Mutant p53 Prolongs NF-κB Activation and Promotes Chronic Inflammation and Inflammation-Associated Colorectal Cancer

Cooks, T., Pateras, I. S., Tarcic, O., Solomon, H., Schetter, A. J., Wilder, S., Lozano, G., Pikarsky, E., Forshew, T., Rozenfeld, N., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.022 · Cited by 478

Identification of a novel p53 functional domain that is necessary for efficient growth suppression

Walker, K. K., & Levine, A. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15335 · Cited by 477

Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling

Weissmueller, S., Manchado, E., Saborowski, M., Morris, J. P., Wagenblast, E., Davis, C. A., Moon, S.-H., Pfister, N. T., Tschaharganeh, D. F., Kitzing, T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.066 · Cited by 466

Targeting the ERBB family in cancer: couples therapy

Tebbutt, N. C., Pedersen, M. W., & Johns, T. G. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3559 · Cited by 464

p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM

Song, H., Hollstein, M., & Xu, Y. (2007) · Nature Cell Biology · doi:10.1038/ncb1571 · Cited by 456

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53

Wang, Q., Fan, S., Eastman, A., Worland, P. J., Sausville, E. A., & O'Connor, P. M. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.14.956 · Cited by 453

Structure–function–rescue: the diverse nature of common p53 cancer mutants

Joerger, A. C., & Fersht, A. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210291 · Cited by 442

Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

Blandino, G., Levine, A. J., & Oren, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202314 · Cited by 439

Small peptides activate the latent sequence-specific DNA binding function of p53

Hupp, T. R., Sparks, A., & Lane, D. P. (1995) · Cell · doi:10.1016/0092-8674(95)90165-5 · Cited by 439

Tumour-associated mutant p53 drives the Warburg effect

Zhang, C., Liu, J., Liang, Y., Wu, R., Zhao, Y., Hong, X., Lin, M., Yu, H., Liu, L., Levine, A. J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3935 · Cited by 434

The role of mutant p53 in human cancer

Goh, A. M., Coffill, C. R., & Lane, D. P. (2010) · The Journal of Pathology · doi:10.1002/path.2784 · Cited by 408

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 398

High Incidence of Lung, Bone, and Lymphoid Tumors in Transgenic Mice Overexpressing Mutant Alleles of the p53 Oncogene

Lavigueur, A., Maltby, V., Mock, D., Rossant, J., Pawson, T. J., & Bernstein, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.9.3982 · Cited by 393

The first five years of single-cell cancer genomics and beyondPreprint

Navin, N. E. (2015) · Genome Research · doi:10.1101/gr.191098.115 · Cited by 377

p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis

Kemp, C. J., Wheldon, T. E., & Balmain, A. (1994) · Nature Genetics · doi:10.1038/ng0994-66 · Cited by 370

The inherent instability of mutant p53 is alleviated by Mdm2 or p16 INK4a lossPreprint

Terzian, T., Suh, Y., Iwakuma, T., Post, S. M., Neumann, M., Lang, G. A., Pelt, C. S. V., & Lozano, G. (2008) · Genes & Development · doi:10.1101/gad.1662908 · Cited by 363

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment

Alexandrova, E. M., Yallowitz, A. R., Li, D., Xu, S., Schulz‐Heddergott, R., Proia, D. A., Lozano, G., Dobbelstein, M., & Moll, U. M. (2015) · Nature · doi:10.1038/nature14430 · Cited by 359

Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum

Kress, M., May, E., Cassingena, R., & May, P. (1979) · Journal of Virology · doi:10.1128/jvi.31.2.472-483.1979 · Cited by 359

TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response

Zhou, G., Liu, Z., & Myers, J. N. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25592 · Cited by 355

Results of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia

Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0481 · Cited by 352

Identification of a Minimal Transforming Domain of p53: Negative Dominance through Abrogation of Sequence-Specific DNA Binding

Shaulian, E., Zauberman, A., Ginsberg, D., & Oren, M. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5581 · Cited by 343

Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain

Selivanova, G., Iotsova, V., Okan, İ., Fritsche, M., Ström, M., Groner, B., Grafström, R. C., & Wiman, K. G. (1997) · Nature Medicine · doi:10.1038/nm0697-632 · Cited by 341

A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas

Soragni, A., Janzen, D. M., Johnson, L. M., Lindgren, A. G., Thai-Quynh Nguyen, A., Tiourin, E., Soriaga, A. B., Lu, J., Jiang, L., Faull, K. F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.002 · Cited by 341

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

Li, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336

Allele-Specific p53 Mutant Reactivation

Yu, X., Vázquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 321

Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus

Mowat, M. R. A., Cheng, A., Kimura, N., Bernstein, A., & Benchimol, S. (1985) · Nature · doi:10.1038/314633a0 · Cited by 320

Clinical Overview of MDM2/X-Targeted Therapies

Burgess, A., Chia, K. M., Haupt, S., Thomas, D., Haupt, Y., & Lim, E. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00007 · Cited by 315

p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products

Yin, Y., Stephen, C. W., Luciani, M. G., & Fåhræus, R. (2002) · Nature Cell Biology · doi:10.1038/ncb801 · Cited by 305

The rebel angel: mutant p53 as the driving oncogene in breast cancer

Walerych, D., Napoli, M., Collavin, L., & Sal, G. D. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs232 · Cited by 301

p53 Efficiently Suppresses Tumor Development in the Complete Absence of Its Cell-Cycle Inhibitory and Proapoptotic Effectors p21, Puma, and Noxa

Valente, L. J., Gray, D. H. D., Michalak, E. M., Hofbauer, J. P., Egle, A., Scott, C. L., Janic, A., & Strasser, A. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.012 · Cited by 299

A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer

DiGiammarino, E. L., Lee, A. S., Cadwell, C., Zhang, W., Bothner, B. B., Ribeiro, R. C., Zambetti, G. P., & Kriwacki, R. W. (2001) · Nature Structural Biology · doi:10.1038/nsb730 · Cited by 293

Next-generation sequencing to guide cancer therapy

Gagan, J., & Allen, E. M. V. (2015) · Genome Medicine · doi:10.1186/s13073-015-0203-x · Cited by 293

A Pin1/Mutant p53 Axis Promotes Aggressiveness in Breast Cancer

Girardini, J. E., Napoli, M., Piazza, S., Rustighi, A., Marotta, C., Radaelli, E., Capaci, V., Jordan, L. B., Quinlan, P., Thompson, A., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.004 · Cited by 290

Li-Fraumeni syndrome: cancer risk assessment and clinical management

McBride, K. A., Ballinger, M. L., Killick, E., Kirk, J., Tattersall, M. H. N., Eeles, R. A., Thomas, D. M., & Mitchell, G. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.41 · Cited by 286

Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis

Hanel, W. G., Marchenko, N. D., Xu, S., Yu, S., Weng, W., & Moll, U. M. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.17 · Cited by 278

Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer

Wei, S., Kozono, S., Kats, L., Nechama, M., Li, W., Guarnerio, J., Luo, M., You, M.-H., Yao, Y., Kondo, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3839 · Cited by 272

ΔN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53

Courtois-Cox, S., Verhaegh, G. W. C. T., North, S., Luciani, M. G., Lassus, P., Hibner, U., Oren, M., & Hainaut, P. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205874 · Cited by 264

TP53 and gastric carcinoma: A review

Fenoglio‐Preiser, C. M., Wang, J., Stemmermann, G. N., & Noffsinger, A. E. (2003) · Human Mutation · doi:10.1002/humu.10180 · Cited by 252

Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene

Wolf, D., Harris, N., & Rotter, V. (1984) · Cell · doi:10.1016/0092-8674(84)90532-4 · Cited by 247

Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs

Bykov, V. J. N., Issaeva, N., Zache, N., Shilov, A., Hultcrantz, M., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501664200 · Cited by 247

Small molecule induced reactivation of mutant p53 in cancer cells

Liu, X., Wilcken, R., Joerger, A. C., Chuckowree, I., Amin, J., Spencer, J., & Fersht, A. R. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt305 · Cited by 246

Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer

Walerych, D., Lisek, K., Sommaggio, R., Piazza, S., Ciani, Y., Dalla, E., Rajkowska, K., Gaweda-Walerych, K., Ingallina, E., Tonelli, C., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3380 · Cited by 239

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models

Ma, C. X., Cai, S., Li, S., Ryan, C. E., Guo, Z., Schaiff, W. T., Li, L., Hoog, J., Goiffon, R., Prat, A., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58765 · Cited by 227

Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53

Wassman, C. D., Baronio, R., Demir, Ö., Wallentine, B. D., Chen, C.-K., Hall, L., Salehi, F., Lin, D., Chung, B. P., Hatfield, G. W., et al. (2013) · Nature Communications · doi:10.1038/ncomms2361 · Cited by 226

The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families

Achatz, M. I., Olivier, M., Calvez‐Kelm, F. L., Martel‐Planche, G., Lopes, A., Rossi, B. M., Ashton‐Prolla, P., Giugliani, R., Palmero, E. I., Vargas, F. R., et al. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.12.039 · Cited by 218

Synthetic small inhibiting RNAs: Efficient tools to inactivate oncogenic mutations and restore p53 pathways

Martinez, L. A., Naguibneva, I., Lehrmann, H., Vervisch, A., Tchénio, T., Lozano, G., & Harel-Bellan, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222406899 · Cited by 210

Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.

Wang, Y., Li, J., Booher, R. N., Kraker, A. J., Lawrence, T. S., Leopold, W. R., & Sun, Y. (2001) · PubMed · Cited by 210

Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53

Teufel, D. P., Freund, S. M. V., Bycroft, M., & Fersht, A. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702010104 · Cited by 207

Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression

Bossi, G., Lapi, E., Strano, S., Rinaldo, C., Blandino, G., & Sacchi, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209026 · Cited by 202

The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis

Fontemaggi, G., Dell’Orso, S., Trisciuoglio, D., Shay, T., Melucci, E., Fazi, F., Terrenato, I., Mottolese, M., Muti, P. C., Domany, E., et al. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1669 · Cited by 195

Activation of the cryptic DNA binding function of mutant forms of p53

Hupp, T. R., Meek, D. W., Midgley, C., & Lane, D. P. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.14.3167 · Cited by 190

Mutant p53 reactivation by small molecules makes its way to the clinic

Bykov, V. J. N., & Wiman, K. G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.04.017 · Cited by 181

Screening thep53 status of human cell lines using a yeast functional assay

Jia, L., Osada, M., Ishioka, C., Gamo, M., Ikawa, S., Suzuki, T., Shimodaira, H., Niitani, T., Kudo, T., Akiyama, M., et al. (1997) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199708)19:4 · Cited by 178

Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells

Sarig, R., Rivlin, N., Brosh, R., Bornstein, C., Kamer, I., Ezra, O., Molchadsky, A., Goldfinger, N., Brenner, O. J., & Rotter, V. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20100797 · Cited by 162

Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells

Deb, S., Jackson, C. T., Subler, M. A., & Martin, D. W. (1992) · Journal of Virology · doi:10.1128/jvi.66.10.6164-6170.1992 · Cited by 160

How Many Mutant p53 Molecules Are Needed To Inactivate a Tetramer?

Chan, W. M., Siu, W. Y., Lau, A. W. S., & Poon, R. Y. C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3536-3551.2004 · Cited by 159

Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations

Brachmann, R. K., Yu, K., Eby, Y. J., Pavletich, N. P., & Boeke, J. D. (1998) · The EMBO Journal · doi:10.1093/emboj/17.7.1847 · Cited by 157

COTI-2, a novel small molecule that is active against multiple human cancer cell linesin vitroandin vivo

Salim, K. Y., Vareki, S. M., Danter, W. R., San‐Marina, S., & Koropatnick, J. D. (2016) · Oncotarget · doi:10.18632/oncotarget.9133 · Cited by 155

Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer

Schuler, P. J., Harasymczuk, M., Visús, C., DeLeo, A. B., Trivedi, S., Lei, Y. L., Argiris, A. E., Gooding, W. E., Butterfield, L. H., Whiteside, T. L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2617 · Cited by 152

Tumor-Derived p53 Mutants Induce NF-κB2 Gene Expression

Scian, M. J., Stagliano, K. E., Anderson, M. A. E., Hassan, S., Bowman, M., Miles, M. F., Deb, S. P., & Deb, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.22.10097-10110.2005 · Cited by 152

Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity

Candau, R., Scolnick, D. M., Darpino, P., Ying, C. Y., Halazonetis, T. D., & Berger, S. L. (1997) · Oncogene · doi:10.1038/sj.onc.1201244 · Cited by 152

Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53

Vikhanskaya, F., Lee, M. K., Mazzoletti, M., Broggini, M., & Sabapathy, K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm099 · Cited by 145

Direct regulation of the centrosome duplication cycle by the p53-p21Waf1/Cip1 pathway

Tarapore, P., Horn, H. F., Tokuyama, Y., & Fukasawa, K. (2001) · Oncogene · doi:10.1038/sj.onc.1204424 · Cited by 145

Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 Binding

Wang, W., Takimoto, R., Rastinejad, F., & El‐Deiry, W. S. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.6.2171-2181.2003 · Cited by 144

Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers

Dearth, L. R., Hua, Q., Wang, T., Baroni, T. E., Zeng, J., Chen, S. W., Yi, S. Y., & Brachmann, R. K. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl132 · Cited by 139

Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF)

Tan, B. S., Tiong, K. H., Choo, H. L., Chung, F. F., Hii, L., Tan, S. H., Yap, I. K., Pani, S., Khor, N. T., Wong, S. F., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.191 · Cited by 138

Targeting p53 for enhanced radio- and chemo-sensitivity

Lü, C., & El‐Deiry, W. S. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0330-1 · Cited by 137

Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation

Wang, Y., Suh, Y., Fuller, M. Y., Jackson, J. G., Xiong, S., Terzian, T., Quintás‐Cardama, A., Bankson, J. A., El‐Naggar, A. K., & Lozano, G. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44504 · Cited by 137

Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression

Nozaki, M., Tada, M., Kobayashi, H., Zhang, C. L., Sawamura, Y., Abe, H., Ishii, N., & Meir, E. G. V. (1999) · Neuro-Oncology · doi:10.1093/neuonc/1.2.124 · Cited by 126

Mutant p53 targeting by the low molecular weight compound STIMA‐1

Zache, N., Lambert, J. M. R., Rökaeus, N., Shen, J., Hainaut, P. L., Bergman, J., Wiman, K. G., & Bykov, V. J. N. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.02.004 · Cited by 120

High Incidence of Lung, Bone, and Lymphoid Tumors in Transgenic Mice Overexpressing Mutant Alleles of the p53 Oncogene

Lavigueur, A., Maltby, V., Mock, D., et al. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.9.3982-3991.1989 · Cited by 113

Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells.

Reihsaus, E., Kohler, M., Kraiss, S., Oren, M., & Montenarh, M. (1990) · PubMed · Cited by 109

A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis

Weinmann, L., Wischhusen, J., Demma, M. J., Naumann, U., Roth, P., Dasmahapatra, B., & Weller, M. (2008) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402301 · Cited by 108

SCH529074, a Small Molecule Activator of Mutant p53, Which Binds p53 DNA Binding Domain (DBD), Restores Growth-suppressive Function to Mutant p53 and Interrupts HDM2-mediated Ubiquitination of Wild Type p53

Demma, M. J., Maxwell, E., Ramos, R., Liang, L., Li, C., Hesk, D., Rossman, R. R., Mallams, A. K., Doll, R. J., Liu, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.083469 · Cited by 105

Cell-type, Dose, and Mutation-type Specificity Dictate Mutant p53 Functions In Vivo

Lee, M. K., Teoh, W. W., Phang, B. H., Tong, W., Wang, Z. Q., & Sabapathy, K. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.022 · Cited by 104

Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth

Aggarwal, M., Saxena, R., Sinclair, E., Fu, Y., Jacobs, A., Dyba, M., Wang, X., Cruz, I., Berry, D., Kallakury, B., et al. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2016.48 · Cited by 101

Characterization of p53 oligomerization domain mutations isolated from Li–Fraumeni and Li–Fraumeni like family members

Lomax, M. E., Barnes, D. M., Hupp, T. R., Picksley, S. M., & Camplejohn, R. (1998) · Oncogene · doi:10.1038/sj.onc.1201974 · Cited by 100

Design of a molecular support for cryo-EM structure determination

Martin, T. G., Bharat, T. A. M., Joerger, A. C., Bai, X., Praetorius, F., Fersht, A. R., Dietz, H., & Scheres, S. H. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612720113 · Cited by 100

Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity

Xu, J., Wang, J., Hu, Y., Qian, J., Xu, B., Chen, H., Zou, W., & Fang, J.-Y. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.75 · Cited by 98

Clinical Relevance of Gain-Of-Function Mutations of p53 in High-Grade Serous Ovarian Carcinoma

Kang, H. J., Chun, S., Kim, K.-R., Sohn, I., & Sung, C. O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072609 · Cited by 98

Deletion of 5'-coding sequences of the cellular p53 gene in mouse erythroleukemia: a novel mechanism of oncogene regulation.

Rovinski, B., Munroe, D. G., Peacock, J. W., Mowat, M. R. A., Bernstein, A., & Benchimol, S. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.2.847 · Cited by 96

Synthetic Metallochaperone ZMC1 Rescues Mutant p53 Conformation by Transporting Zinc into Cells as an Ionophore

Blanden, A. R., Yu, X., Wolfe, A. J., Gilleran, J., Augeri, D. J., O’Dell, R. S., Olson, E. C., Kimball, S. D., Emge, T. J., Movileanu, L., et al. (2015) · Molecular Pharmacology · doi:10.1124/mol.114.097550 · Cited by 86

Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis

Hiraki, M., Hwang, S.-Y., Cao, S., Ramadhar, T. R., Byun, S., Yoon, K. W., Lee, J. H., Chu, K., Gurkar, A. U., Kolev, V., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.07.016 · Cited by 81

Mining the National Cancer Institute Anticancer Drug Discovery Database: Cluster Analysis of Ellipticine Analogs with p53-Inverse and Central Nervous System-Selective Patterns of Activity

Shi, L. M., Myers, T. G., Fan, Y., O'Connor, P. M., Paull, K. D., Friend, S. H., & Weinstein, J. N. (1998) · Molecular Pharmacology · doi:10.1124/mol.53.2.241 · Cited by 78

The evolution of thymic lymphomas in p53 knockout micePreprint

Dudgeon, C., Chan, C. H., Kang, W., Sun, Y., Emerson, R., Robins, H. S., & Levine, A. J. (2014) · Genes & Development · doi:10.1101/gad.252148.114 · Cited by 77

Restoration of wild‐type conformation and activity of a temperature‐sensitive mutant of p53 (p53V272M) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE‐1

North, S., Pluquet, O., Maurici, D., Ghissassi, F. E., & Hainaut, P. L. (2002) · Molecular Carcinogenesis · doi:10.1002/mc.10038 · Cited by 75

Evaluation of the Combined Effect of p53 Codon 72 Polymorphism and Hotspot Mutations in Response to Anticancer Drugs

Vikhanskaya, F., Siddique, M. M., Lee, M. K., Broggini, M., & Sabapathy, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1547 · Cited by 75

Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11

Noll, J. E., Jeffery, J., Al‐Ejeh, F., Kumar, R., Khanna, K. K., Callen, D. F., & Neilsen, P. M. (2011) · Oncogene · doi:10.1038/onc.2011.456 · Cited by 75

Energy requirement for degradation of tumor-associated protein p53.

Gronostajski, R. M., Goldberg, A. L., & Pardee, A. B. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.3.442 · Cited by 73

p53 Oligomerization Is Essential for Its C-terminal Lysine Acetylation

Itahana, Y., Ke, H., & Zhang, Y. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805696200 · Cited by 73

Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides

Tal, P., Eizenberger, S., Cohen, E., Goldfinger, N., Pietrokovski, S., Oren, M., & Rotter, V. (2016) · Oncotarget · doi:10.18632/oncotarget.7857 · Cited by 73

Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model

Kucab, J. E., Phillips, D. H., & Arlt, V. M. (2010) · FEBS Journal · doi:10.1111/j.1742-464x.2010.07676.x · Cited by 70

Dissecting functional roles of p53 N‐terminal transactivation domains by microarray expression analysis

Ohki, R., Kawase, T., Ohta, T., Ichikawa, H., & Taya, Y. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00375.x · Cited by 64

Does p53 status influence tumor response to anticancer therapies?

Pirollo, K. F., Bouker, K. B., & Chang, E. H. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200007000-00002 · Cited by 64

Promyelocytic Leukemia Protein is Required for Gain of Function by Mutant p53

Haupt, S., Agostino, S. D., Mizrahi, I., Alsheich-Bartok, O., Voorhoeve, M., Damalas, A., Blandino, G., & Haupt, Y. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4010 · Cited by 62

Mutant p53R270H gain of function phenotype in a mouse model for oncogene‐induced mammary carcinogenesis

Heinlein, C., Krepulat, F., Löhler, J., Speidel, D., Deppert, W., & Tolstonog, G. V. (2007) · International Journal of Cancer · doi:10.1002/ijc.23317 · Cited by 59

Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins.

El-Hizawi, S., Lagowski, J. P., Kulesz-Martin, M. F., & Albor, A. (2002) · PubMed · Cited by 56

Dosage‐dependent dominance over wild‐type p53 of a mutant p53 isolated from nasopharyngeal carcinoma 1

Sun, Y., Dong, Z., Nakamura, K., & Colburn, N. H. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.10.8344492 · Cited by 54

Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression

Nozaki, M., Tada, M., Kobayashi, H., Zhang, C.-L., Sawamura, Y., Abe, H., Ishii, N., & Meir, E. G. V. (1999) · Neuro-Oncology · doi:10.1215/s1522851798000179 · Cited by 53

Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock‐in (Hupki) mouse model

Kucab, J. E., Phillips, D. H., & Arlt, V. M. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07676.x · Cited by 50

The N-Terminally Truncated p53 Isoform △40p53 Influences Prognosis in Mucinous Ovarian Cancer

Hofstetter, G., Berger, A., Berger, R., Zorić, A., Braicu, E. I., Reimer, D., Fiegl, H., Marth, C., Zeimet, A. G., Ulmer, H., et al. (2012) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31823ca031 · Cited by 46

The Contrived Mutant p53 Oncogene – Beyond Loss of Functions

Sabapathy, K. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00276 · Cited by 45

Prognostic implications of circulating anti-p53 antibodies in lung cancer - a review

Kumar, S., Mohan, A., & Guleria, R. (2009) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2008.01019.x · Cited by 41

Assessing the Efficacy of Mdm2/Mdm4-Inhibiting Stapled Peptides Using Cellular Thermal Shift Assays

Tan, B. X., Brown, C. J., Ferrer, F. J., Yuen, T. Y., Quah, S. T., Chan, B. H., Jansson, A. E., Teo, H., Nordlund, P., & Lane, D. P. (2015) · Scientific Reports · doi:10.1038/srep12116 · Cited by 40

Simple identification of dominant p53 mutants by a yeast functional assay

Inga, A. (1997) · Carcinogenesis · doi:10.1093/carcin/18.10.2019 · Cited by 40

p53 and Hereditary Cancer

Merino, D. M., & Malkin, D. M. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_1 · Cited by 39

Energy Requirement for Degradation of Tumor-Associated Protein p53

Gronostajski, R. M., Goldberg, A. L., & Pardee, A. B. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.3.442-448.1984 · Cited by 39

Amino-terminal p53 mutations lead to expression of apoptosis proficient p47 and prognosticate better survival, but predispose to tumorigenesis

Phang, B. H., Othman, R., Bougeard, G., Chia, R. H., Frébourg, T., Tang, C. L., Cheah, P. Y., & Sabapathy, K. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510043112 · Cited by 37

COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis.

Zhou, X., Wang, X. W., Xu, L., Hagiwara, K., Nagashima, M., Wolkowicz, R., Zurer, I., Rotter, V., & Harris, C. C. (1999) · PubMed · Cited by 37

Awaiting a New Era of Cancer Immunotherapy

Hong, C. W., & Zeng, Q. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0063 · Cited by 32

The R246S hot-spot p53 mutant exerts dominant-negative effects in embryonic stem cells in vitro and in vivo

Lee, M. K., & Sabapathy, K. (2008) · Journal of Cell Science · doi:10.1242/jcs.022822 · Cited by 31

Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities

Iyer, S. V., Parrales, A., Begani, P., Narkar, A., Adhikari, A. S., Martinez, L. A., & Iwakuma, T. (2015) · Oncotarget · doi:10.18632/oncotarget.6634 · Cited by 31

Insights into Wild-Type and Mutant p53 Functions Provided by Genetically Engineered Mice

Donehower, L. A. (2014) · Human Mutation · doi:10.1002/humu.22507 · Cited by 30

Deletion of 5′-coding Sequences of the Cellular p53 Gene in Mouse Erythroleukemia: A Novel Mechanism of Oncogene Regulation

Rovinski, B., Munroe, D. G., Peacock, J., et al. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.2.847-853.1987 · Cited by 30

Disruption of an intermonomer salt bridge in the p53 tetramerization domain results in an increased propensity to form amyloid fibrils

Galea, C. A., Bowman, P., & Kriwacki, R. W. (2005) · Protein Science · doi:10.1110/ps.051622005 · Cited by 27

Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53

Bristow, R. G., Peacock, J. W., Jang, A., Kim, J., Hill, R. P., & Benchimol, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206405 · Cited by 23

Role of tumor suppressor genes in transplacental lung carcinogenesis

Rollins, L. A., Leone‐Kabler, S., O’Sullivan, M. G., & Miller, M. S. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199803)21:3 · Cited by 23

A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.

Plummer, S. J., Santibanez‐Koref, M., Kurosaki, T., Liao, S., Noble, B., Fain, P. R., Anton‐Culver, H., & Casey, G. (1994) · PubMed · Cited by 20

The application of gene therapy in China.

Peng, Z., Qing, Y., & Li, B. (2008) · PubMed · Cited by 19

Fischer 344-Tp53 knockout rats exhibit a high rate of bone and brain neoplasia with frequent metastasis

Hansen, S. A., Hart, M. L., Busi, S. B., Parker, T. W., Goerndt, A., Jones, K. B., Amos-Landgraf, J. M., & Bryda, E. C. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.025767 · Cited by 19

P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH

Forslund, A., Kressner, U., Lönnroth, C., Andersson, M., Lindmark, G. E., & Lundholm, K. (2002) · International Journal of Oncology · doi:10.3892/ijo.21.2.409 · Cited by 16

Anin silicoalgorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein

Bromley, D., Bauer, M. R., Fersht, A. R., & Daggett, V. (2016) · Protein Engineering Design and Selection · doi:10.1093/protein/gzw035 · Cited by 16

p53 as an Effector or Inhibitor of Therapy ResponsePreprint

Ablain, J., Poirot, B., Esnault, C., Lehmann‐Che, J., & de Thé, H. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026260 · Cited by 15

Prevalence of Allelic Loss at TP53 in Endometrial Carcinomas

Semczuk, A., Schneider‐Stock, R., & Szewczuk, W. (2010) · Oncology · doi:10.1159/000314353 · Cited by 12

TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays

Lin, C., Chen, I.-C., Huang, C., Hu, F., Kuo, W., Kuo, K., Wang, C., Wu, P., Chang, D., Wang, M., et al. (2015) · Scientific Reports · doi:10.1038/srep17879 · Cited by 12

PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein

Stuber, G., Flaberg, E., Petrányi, G., Ötvös, R. H.-G., Rökaeus, N., Kashuba, E., Wiman, K. G., Klein, G., & Székely, L. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-23 · Cited by 8

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016

Regulated cell death (RCD) in cancer: key pathways and targeted therapies

Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C. Y., Fu, L., Chen, Y., & Han, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01110-y · Cited by 895

Drugging p53 in cancer: one protein, many targets

Hassin, O., & Oren, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 771

Circular RNA Vaccines against SARS-CoV-2 and Emerging Variants

Qu, L., Yi, Z., Shen, Y., Lin, L., Chen, F., Xu, Y., Wu, Z., Tang, H., Zhang, X., Tian, F., et al. (2021) · doi:10.1101/2021.03.16.435594 · Cited by 636

Somatic mutations precede acute myeloid leukemia years before diagnosis

Desai, P., Mencia-Trinchant, N., Savenkov, O., Simon, M. S., Cheang, G., Lee, S., Samuel, M., Ritchie, E. K., Guzman, M. L., Ballman, K. V., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0081-z · Cited by 619

Targeting mutant p53 for cancer therapy

Oren, M., Tal, P., & Rotter, V. (2016) · Aging · doi:10.18632/aging.100992 · Cited by 23

Mutant p53 in Cancer Progression and Targeted Therapies

Zhu, G., Pan, C., Bei, J., Li, B., Chen, L., Xu, Y., & Fu, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.595187 · Cited by 230

Targeting Therapies for the p53 Protein in Cancer Treatments

Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84

p53: from understanding its structure to advances in therapeutic targeting

Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 29

Molecularly targeted therapies for p53-mutant cancers

Zhao, D., Tahaney, W. M., Mazumdar, A., Savage, M. I., & Brown, P. H. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2575-0 · Cited by 82